Contactless Assessment of Patient Vital Signs for Triage Using Remote Photoplethysmography in the Emergency Department
Launched by THE UNIVERSITY OF HONG KONG · Jul 30, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new, contactless way to measure vital signs (like heart rate and blood pressure) using a technology called remote photoplethysmography (rPPG). This method uses a camera, such as those on smartphones, to analyze subtle changes in skin color that occur when blood flows beneath the skin. By doing this, the researchers hope to see if this technology can accurately estimate vital signs without needing to touch the patient. The study will involve adult patients who come to the Accident and Emergency Department at Queen Mary Hospital between August and October 2024.
To participate, you must be at least 18 years old and able to give written consent. If you are a stable patient categorized as semi-urgent or non-urgent, you may be eligible. During the study, participants will sit still while both the contactless method and a standard manual method are used to measure vital signs at the same time. The researchers will also ask how comfortable participants feel with each method. This study aims to see how well the contactless technology works compared to traditional methods and to understand patients’ experiences with these different ways of measuring vital signs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age \>/= 18 years
- • a valid written consent
- Exclusion Criteria:
- • age \< 18 years
- • refusal of consent/pre-existing mental illness rending consent impossible
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, None Selected, Hong Kong
Patients applied
Trial Officials
Rex Pui Kin Lam, MBBS, FHKCEM
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported